Literature DB >> 11514262

Vascular endothelial dysfunction: does tetrahydrobiopterin play a role?

Z S Katusic1.   

Abstract

Tetrahydrobiopterin is one of the most potent naturally occurring reducing agents and an essential cofactor required for enzymatic activity of nitric oxide synthase (NOS). The exact role of tetrahydrobiopterin in the control of NOS catalytic activity is not completely understood. Existing evidence suggests that it can act as allosteric and redox cofactors. Suboptimal concentration of tetrahydrobiopterin reduces formation of nitric oxide and favors "uncoupling" of NOS leading to NOS-mediated reduction of oxygen and formation of superoxide anions and hydrogen peroxide. Recent findings suggest that accelerated catabolism of tetrahydrobiopterin in arteries exposed to oxidative stress may contribute to pathogenesis of endothelial dysfunction present in arteries exposed to hypertension, hypercholesterolemia, diabetes, smoking, and ischemia-reperfusion. Beneficial effects of acute and chronic tetrahydrobiopterin supplementation on endothelial function have been reported in experimental animals and humans. Furthermore, it appears that beneficial effects of some antioxidants (e.g., vitamin C) on vascular function could be mediated via increased intracellular concentration of tetrahydrobiopterin. In this review, the potential role of tetrahydrobiopterin in the pathogenesis of vascular endothelial dysfunction and mechanisms underlying beneficial vascular effects of tetrahydrobiopterin will be discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514262     DOI: 10.1152/ajpheart.2001.281.3.H981

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  58 in total

1.  More sweetness than light? A search for the causes of diabetic vasculopathy.

Authors:  J Igarashi; T Michel
Journal:  J Clin Invest       Date:  2001-11       Impact factor: 14.808

Review 2.  NO and the vasculature: where does it come from and what does it do?

Authors:  Karen L Andrews; Chris R Triggle; Anthie Ellis
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 3.  Age-related endothelial dysfunction : potential implications for pharmacotherapy.

Authors:  Rachel L Matz; Ramaroson Andriantsitohaina
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 4.  Cerebral vascular dysregulation in the ischemic brain.

Authors:  Alexander Kunz; Costantino Iadecola
Journal:  Handb Clin Neurol       Date:  2009

5.  Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice.

Authors:  Masanori Ozaki; Seinosuke Kawashima; Tomoya Yamashita; Tetsuaki Hirase; Masayuki Namiki; Nobutaka Inoue; Ken-ichi Hirata; Hiroyuki Yasui; Hiromu Sakurai; Yuichi Yoshida; Masahiro Masada; Mitsuhiro Yokoyama
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 6.  Metabolic syndrome and endothelial dysfunction.

Authors:  Alessia Fornoni; Leopoldo Raij
Journal:  Curr Hypertens Rep       Date:  2005-04       Impact factor: 5.369

7.  The endothelium in health and disease: A discussion of the contribution of non-nitric oxide endothelium-derived vasoactive mediators to vascular homeostasis in normal vessels and in type II diabetes.

Authors:  Chris R Triggle; Hong Ding; Todd J Anderson; Malarvannan Pannirselvam
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

8.  Cytochrome P-450 2C9 signaling does not contribute to age-associated vascular endothelial dysfunction in humans.

Authors:  Anthony J Donato; Iratxe Eskurza; Kristen L Jablonski; Lindsey B Gano; Gary L Pierce; Douglas R Seals
Journal:  J Appl Physiol (1985)       Date:  2008-07-31

Review 9.  Cellular signaling and NO production.

Authors:  Thomas Michel; Paul M Vanhoutte
Journal:  Pflugers Arch       Date:  2010-01-16       Impact factor: 3.657

Review 10.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.